Search PubMed⌕ Search

Biomedical subjects

J Schlaepfer

Publications and source records attributed to J Schlaepfer.

11 recordsLinked to original sources
PubMed2000

Evidence rather than costs must guide use of the implantable cardioverter defibrillator.

Randomized controlled trials have shown superior survival rates with implantable cardioverter defibrillators (ICDs) compared with antiarrhythmic drugs in survivors of cardiac arrest and life-threatening ventricular tachyarrhythmias, as well as in high-risk patients with ischemic heart disease and inducible ventricular tachycardia (VT). Current defibrillators are small and implanted with techniques similar to standard pacemakers. They provide high-energy shocks for ventricular fibrillation (VF) and rapid VT, antitachycardia pacing for monomorphic VT, and antibradycardia pacing. Limited evidence suggests that ICD therapy is cost-effective when compared with other widely accepted treatments. The use of ICDs is likely to continue to expand in the future. Ongoing clinical trials will define further prophylactic indications of the ICD and clarify its cost-effectiveness ratio in different clinical settings.

Cost-Benefit Analysis↗
PubMed2000

Developing clinical indication for multisite pacing.

The artificial activation of the heart modifies the mechanics of contraction and relaxation. While only little basic research has been addressed to this question, clinical observations showed that for hypertrophic as well as dilated cardiomyopathies appropriate pacing techniques can be useful. Pacing can influence the activation sequence. The spread out from a single site is slow, and so hypercontractility deminshed. With the use of multiple electrodes, two atrial and/or two ventricular, conduction delays in the atria or ventricles can be eliminated. Synchronisation of the cardiac activation has an anti-arrhythmic and positiv inotropic effect. This may lead to new indications for pacemakers or better to be named cardiac synchronisers.

Cardiac Pacing, Artificial↗
PubMed1997

[Sudden death in hypertrophic obstructive and non-obstructive cardiomyopathy: can it be prevented?].

Sudden cardiac death constitutes the most devastating aspect of obstructive and non-obstructive hypertrophic cardiomyopathy. Loss of consciousness and family history of sudden cardiac death should alert the physician to the risk of sudden death. ECG, morphological and hemodynamic assessment, and exploration of central nervous activity are of little use in stratifying the risk of sudden cardiac death. Loss of consciousness associated with nonsustained ventricular tachycardia and inducible sustained ventricular arrhythmia identify patients at very high risk of sudden cardiac death. Nevertheless, many variable factors are involved in the pathophysiology of sudden cardiac death, and hence risk stratification of sudden cardiac death in patients with hypertrophic cardiomyopathy remains a very difficult clinical challenge.

Adolescent↗
PubMed1996

[Cardiac pacemaker dysfunction secondary to outside interference: a review].

Electromagnetic signals from various sources may cause interference with pacemakers. The safety systems developed by manufacturers are generally effective. Nevertheless, some electromagnetic sources, particularly those found in the medical environment, can induce transitory or permanent pacemaker dysfunction. This paper presents the various sources of electromagnetic signals to which a pacemaker may be exposed. Taking into account the available literature, it attempts to clarify those which are really deleterious for the pacemaker and how to avoid them.

Biophysical Phenomena↗
PubMed1994

Relation between cycle length, volume, and pressure in type I atrial flutter.

Assuming that type I atrial flutter is a macroreentrant circuit, its cycle length should vary with the atrial dimensions. In order to test this hypothesis, flutter cycle length was measured while inducing atrial volume and pressure changes by postural and pharmacological means in seven patients undergoing a therapeutic programmed stimulation for type I atrial flutter conversion. Right atrial volume was estimated from B-mode echocardiography data. Basal values were compared with those obtained during inspiration, expiration, Valsalva maneuver, negative tilt (head down), and positive tilt (head up) with 0.8-1.6 mg p.o. nitroglycerin. The right atrial size increased slightly from 17.8 to 18.3 cm2 (P = 0.04) during the pressure load induced by negative tilt (+3 mmHg), with a corresponding lengthening of the flutter cycle length from 228 to 233 msec (P = 0.02). Similarly, pressure unloading of -2 mmHg by positive tilting and nitrates was accompanied by a decrease in right atrial size to 16.6 cm2 (P = 0.04), with a corresponding decrease in cycle length from 228 to 219 msec (P = 0.03). Respiratory maneuver yielded similar results with an inspiratory cycle lengthening, expiratory shortening, and further shortening during Valsalva maneuver. These experiments demonstrate a direct relation between cycle length and atrial volume in human type I atrial flutter. They underline the importance of the right heart preload and atrial size for the electrophysiological characteristics of type I atrial flutter. Beside its fundamental interest, this finding is important for the understanding of the mechanism of maintenance and therapeutic responses of this common arrhythmia.

Atrial Flutter↗
PubMed1994

Autonomic imbalance assessed by heart rate variability analysis in vasovagal syncope.

In this prospective study, the autonomic modulation of the sinus node of 12 patients (mean age 28 +/- 7 years) suffering from vasovagal syncope (VVS) was compared to that of 11 sex and age matched control patients (mean age 32 +/- 4 years) by analysis of heart rate variability. Spectral indices (low frequency power [Plf], high frequency power [Phf], total power [Pt], sympathovagal balance [LF/HF]) and temporal indices, the mean of all coupling intervals between normal beats (mRR), the standard deviation about the mean (sdRR), the percentage of adjacent R to R intervals differing by more than 50 msec (pNN50), and the root mean square of variations in successive R to R intervals (rMSSD) were compared at baseline and during head-up tilt between and within groups. Baseline results were similar in both groups. During tilt testing, comparison of results between groups revealed only significantly higher sdRR and rMSSD and lower LF/HF ratio in VVS patients. Within VVS patients, comparison of temporal and spectral analysis between baseline and tilt showed a significant increase of most indices (Plf, Phf, Pt, sdRR, and rMSSD) but a comparable LF/HF ratio; in contrast, control patients exhibited only a significant increase of LF/HF ratio. In conclusion, VVS patients who developed vasovagal syncope during head-up tilt demonstrated a nonreciprocal modulation of the sinus node by the autonomic nervous system indicative of a pronounced physiological sympathetic surge along with a paradoxical vagal input to the cardiovascular system.

Adult↗
PubMed1993

Acute and long-term ventricular stimulation thresholds with a new, iridium oxide-coated electrode.

Efforts have been made to design electrodes that significantly reduce not only the acute and chronic stimulation thresholds, but also attenuate the early peaking phenomenon and polarization. At two voltage levels (2.7 V and 5.4 V, respectively), we evaluated the right ventricular stimulation thresholds obtained with a new, iridium oxide-coated electrode in ten patients who received a VVI pacemaker. Measurements were made at implant and at multiple intervals for 1 year. Pulse width stimulation thresholds at implant were as follow: 0.04 +/- 0.008 msec at 2.7 V, 0.03 +/- 0.004 msec at 5.4 V; values at 2 weeks were 0.14 +/- 0.06 msec at 2.7 V, 0.07 +/- 0.025 msec at 5.4 V; values at 3 months were 0.09 +/- 0.03 msec at 2.7 V, 0.05 +/- 0.01 msec at 5.4 V; values at 1 year were 0.08 +/- 0.02 msec at 2.7 V, 0.04 +/- 0.01 msec at 5.4 V. The maximal increase of 0.11 +/- 0.05 msec occurred at 2.7 V, 2 weeks after implant. Our results indicate that this new electrode provides low acute and long-term stimulation thresholds, as well as an attenuated early peaking phenomenon, being able to stimulate safely at 2.7 V even early after implant.

Aged↗
PubMed1990

[Sustained ventricular tachycardia: inducibility during invasive electrophysiologic studies].

Electrophysiologic studies are used for diagnosis and treatment in patients with sustained ventricular tachycardia. This method can only be employed if high inducibility of the spontaneous tachycardia can be demonstrated. We therefore investigated prospectively the induction yield in 35 patients with a history of documented sustained ventricular tachycardia. The patients' mean age was 58 years. Coronary artery disease was present in 24 patients, cardiomyopathy in 4, other organic heart diseases in 4, and no heart disease in 3. The ventricular tachycardia induction protocol consisted of three extrastimuli delivered during sinus rhythm and at two pacing cycle lengths, followed by intravenous isoproterenol if no tachycardia was induced before. With the method sustained ventricular tachycardia was induced in 100% of patients with coronary artery disease and cardiomyopathy, in 75% of patients with other heart diseases and in 33% of patients without detectable heart disease. We conclude that electrophysiologic studies have a high yield of sustained ventricular tachycardia induction in patients with underlying organic heart disease. The rational basis for use of electropharmacologic testing therefore exists in these patients. However, in patients without heart disease, the low sensitivity of electrophysiologic studies precludes its use for drug efficacy testing.

Adult↗
PubMed1990

Clinical efficacy of radiofrequency current in the treatment of patients with atrioventricular node reentrant tachycardia.

Eight women (mean age 41 years, range 24 to 62) with drug-resistant atrioventricular (AV) node reentrant tachycardia underwent radiofrequency catheter ablation. Radiofrequency energy was delivered in a unipolar mode with use of a back paddle as the anode placed between the two scapulae. The total applied energy was 2,233 +/- 1,919 J. The AH interval increased from 87 +/- 13 to 113 +/- 17 ms (p less than 0.05) and the PQ interval increased from 141 +/- 15 to 169 +/- 34 ms (p less than 0.05). The anterograde Wenckebach cycle length increased from 300 +/- 41 to 320 +/- 42 ms (p less than 0.05). Retrograde conduction was abolished in five patients. Atrioventricular node tachycardia was still inducible in three patients. During a follow-up period of 9 +/- 3 months, four patients remained clinically asymptomatic without drug therapy and four patients had recurrent symptoms. Three of the latter responded to previously unsuccessful antiarrhythmic drugs and the fourth patient underwent surgical cure for persistence of tachycardia. Right bundle branch block occurred in five patients; it was permanent in four and transient in one. In conclusion, radiofrequency catheter ablation represents a valuable but still investigational therapy in patients with drug-refractory AV node reentrant tachycardia.

Adult↗
PubMed1990

Is there an isolated arrhythmogenic right atrial myocarditis?

Two cases with drug refractory ectopic atrial tachycardia are described. A map-guided partial resection of the right atrium (RA) was done after preoperative endocardial catheter mapping had shown well-defined areas of fractionated RA potentials. Intraoperatively, there were no aneurysmal formations present as described by other authors. Histopathologic examination of the resected tissue showed atrial myocarditis in both patients. Postoperative right ventricular myocardial biopsies revealed no inflammatory tissue. A minor elevation of antibodies against echoviruses was found in one case. Postoperative electrophysiologic studies were negative. We conclude: focal RA myocarditis without concomitant ventricular myocarditis may represent one cause of drug-resistant ectopic atrial tachycardia. Map-guided surgical intervention may cure the disease.

Adult↗